BI
SABS icon

BVF Inc’s SAB Biotherapeutics SABS Stock Holding History

BVF Inc’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-932,697
Closed -$1.87M – 48
2025
Q3 		$1.87M Buy
932,697
+14,871
+2% +$33.6K 0.08% 43
2025
Q2 		$1.61M Hold
917,826
– – 0.06% 41
2025
Q1 		$1.24M Hold
917,826
– – 0.05% 47
2024
Q4 		$3.51M Hold
917,826
– – 0.12% 46
2024
Q3 		$2.48M Hold
917,826
– – 0.07% 46
2024
Q2 		$2.85M Hold
917,826
– – 0.08% 49
2024
Q1 		$4.17M Sell
917,826
-2
-0% -$11 0.11% 49
2023
Q4 		$6.31M Buy
+917,828
New +$7.7M 0.16% 52

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

BVF Inc's SABS Position: Q4 2025 in Review

BVF Inc sold out of SAB Biotherapeutics (SABS) in Q4 2025, closing a stake of 932,697 shares — an estimated $1.87M sold.

BVF Inc first reported a position in SABS in Q4 2023 and held it in 8 quarters. The position peaked at $6.31M in Q4 2023. 48 funds tracked by Wall St. Rank hold SABS as of Q4 2025.

  • BVF Inc reported no remaining SAB Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • BVF Inc sold 932,697 SAB Biotherapeutics shares in Q4 2025, an estimated $1.87M.
  • BVF Inc first reported a position in SAB Biotherapeutics in Q4 2023 and held it in 8 quarters.
  • BVF Inc's SAB Biotherapeutics position peaked at $6.31M in Q4 2023.
  • 48 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2025.

Based on BVF Inc's 13F filing for Q4 2025, filed 17 Feb 2026.